Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track COR with free AI briefings, catalyst countdowns, and dilution alerts.

COR · Cencora, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$2.8B Cash on Hand
CF+ Cash Runway
Follow COR by email Get an email when COR reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about COR, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

💰 Cash Runway & Dilution Risk

COR holds $2.8B in cash and short-term investments (as of Jun 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when COR files for a raise →

👥 Who Owns COR

Insiders 0.2% Institutions (1912 holders) 96.8% Public and other holders 3%
HolderTypeShares% of sharesAs of
Vanguard Capital Management Institution (13G, 5%+) 14,210,260 7.45% 2026-03-31
James F Cleary
Chief Financial Officer
Insider 160,357 0.08% 2026-03-11
Robert P. Mauch
President & CEO, Director · +18,292 options
Insider 90,652 0.05% 2026-11-11
Dermot Mark Durcan
Director
Insider 31,767 0.02% 2026-06-18
Elizabeth S Campbell
Executive Vice President · +4,402 options
Insider 29,682 0.02% 2026-11-11
Silvana Battaglia
Executive Vice President
Insider 23,624 0.01% 2026-06-30
Lon R Greenberg
Director
Insider 17,128 0.01% 2026-09-16
Lazarus Krikorian
SVP & Chief Accounting Officer · +3,216 options
Insider 16,948 0.01% 2026-11-11
Dennis M Nally
Director
Insider 13,294 0.01% 2026-10-30
Pawan Verma
EVP, Chief Data & Info Officer · +2,642 options
Insider 10,077 0.01% 2026-11-12
Lauren M Tyler
Director
Insider 4,547 0.00% 2026-10-30
Lorence H. Kim
Director
Insider 4,081 0.00% 2026-03-05

Share count 190,827,165 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full COR picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for COR and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.